| BMY |
Bristol-Myers Squibb Company |
72%
|
ill decide with respect to the coverage and reimbursement for our product candidates. Also, the containment of healthcare costs has become a priority of federal, state and foreign governments, and th… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from BMY graph: Reciprocal relationship from TLSA graph: ill decide with respect to the covera… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
ill decide with respect to the coverage and reimbursement for our product candidates. Also, the containment of healthcare costs has become a priority of federal, state and foreign governments, and th… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from TLSA graph: ill decide with respect to the co… |
| CRDF |
Cardiff Oncology, Inc. |
72%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| CRDF |
Cardiff Oncology, Inc. |
72%
|
Reciprocal relationship from CRDF graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 20… |
| HEPA |
Hepion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from HEPA graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 20… |
| HEPA |
Hepion Pharmaceuticals, Inc. |
72%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| MANU |
Manchester |
72%
|
Reciprocal relationship from MANU graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 20… |
| MANU |
Manchester |
72%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| OKYO |
OKYO Pharma Limited |
72%
|
The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the abili… |
| OKYO |
OKYO Pharma Limited |
72%
|
Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA graph: The Group has control when it can d… |
| SIGA |
SIGA Technologies, Inc. |
72%
|
Reciprocal relationship from SIGA graph: Reciprocal relationship from TLSA graph: currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing a… |
| SIGA |
SIGA Technologies, Inc. |
72%
|
currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from … |
| ACCUSTEM-SCIENCES-INC |
ACCUSTEM-SCIENCES-INC |
62%
|
he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal of $ 2,000 k plus accrued interest of $ 1,150 k were converted into 2,100,000 Ordi… |
| ACCUSTEM-SCIENCES-INC-GROUP |
ACCUSTEM-SCIENCES-INC-GROUP |
62%
|
s which are summarized below. Market risk Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for manag… |
| ACTAVIA-LIFE-SCIENCES-INC |
ACTAVIA-LIFE-SCIENCES-INC |
62%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| ACTIVIA-LIFESCIENCES-INC |
ACTIVIA-LIFESCIENCES-INC |
62%
|
currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from … |
| ACUT |
AccuStem Sciences, Inc. |
62%
|
Reciprocal relationship from ACUT graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from ACUT graph: Reciprocal relationship from TLSA graph: he 6-month period. In October 2023 … |
| CALLISTO-PHARMACEUTICALS-INC |
CALLISTO-PHARMACEUTICALS-INC |
62%
|
director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was a director of Tamir Biotechnology, Inc. (formerly Alfacell Corpo… |
| FINANCIAL-COMMITMENTS-THE-GROUP |
FINANCIAL-COMMITMENTS-THE-GROUP |
62%
|
he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal of $ 2,000 k plus accrued interest of $ 1,150 k were converted into 2,100,000 Ordi… |
| GENERAL-INFORMATION-TIZIANA-LIFE-SCIENCES-LTD |
GENERAL-INFORMATION-TIZIANA-LIFE-SCIENCES-LTD |
62%
|
y with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient information and reporting cybersecurity incidents to the SEC… |
| GOING-CONCERN-THE-GROUP |
GOING-CONCERN-THE-GROUP |
62%
|
y with extensive regulations, including requirements imposed by the Federal Drug Administration related to adequately safeguarding patient information and reporting cybersecurity incidents to the SEC… |
| GROUP-THE-GROUP |
GROUP-THE-GROUP |
62%
|
l and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value at a pre-tax discount rate. Deferred Income The trea… |
| OKYO-PHARMA-LTD |
OKYO-PHARMA-LTD |
62%
|
he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal of $ 2,000 k plus accrued interest of $ 1,150 k were converted into 2,100,000 Ordi… |
| OKYO-PHARMA-LTD-ACCUSTEM-SCIENCES-LIMITED |
OKYO-PHARMA-LTD-ACCUSTEM-SCIENCES-LIMITED |
62%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| OPERATING-LOSS-THE-GROUP |
OPERATING-LOSS-THE-GROUP |
62%
|
l and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value at a pre-tax discount rate. Deferred Income The trea… |
| PANETTA-PARTNERS-LTD |
PANETTA-PARTNERS-LTD |
62%
|
egy for our business and related financing, are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties. You should read the “Risk Factors” sectio… |
| PATENT-GROUP |
PATENT-GROUP |
62%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| PLANWISE-GROUP-LTD-ACTAVIA-LIFE-SCIENCES-INC |
PLANWISE-GROUP-LTD-ACTAVIA-LIFE-SCIENCES-INC |
62%
|
s which are summarized below. Market risk Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for manag… |
